Neurogene drops after pausing part of gene therapy study due to serious side effect

Neurogene

18/11/2024 12:46

** Drug developer Neurogene's  NGNE.O  shares fall 19% to $28
premarket
    ** Company says it has paused testing high-dosage version of
its experimental gene therapy after reporting a serious
treatment related side-effect in one of the participants
    ** Neurogene says the participant is in critical condition
due to hyperinflammatory syndrome, a rare and life-threatening
immune response
    ** The gene therapy, NGN-401, is being developed to treat
Rett syndrome, a rare genetic neurological disorder that occurs
most often in girls and affects their ability to speak, walk,
eat, and even breathe easily
    ** Company says the U.S. Food and Drug Administration has
allowed the early-mid-stage study to continue testing patients
with the low-dosage version
    ** As of last close, stock up 78% YTD

(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com))